Severe LH Suppressed Patients After Administration of a GnRH Antagonist (OPTOMALH)

This study has been completed.
Sponsor:
Collaborator:
Maccabi Healthcare Services, Israel
Information provided by (Responsible Party):
shahar kol, Assuta Hospital Systems
ClinicalTrials.gov Identifier:
NCT01936077
First received: October 28, 2010
Last updated: September 2, 2013
Last verified: September 2013
  Purpose

The ideal stimulation protocol for ovarian stimulation is under constant debate, as we gain more pharmacological control over the patient hormonal milieu. Specifically, the debate focuses around the ideal LH levels. The concept of an "LH window" was suggested.

The need for a threshold level of LH is clearly demonstrated in hypogonado-tropic hypogonadism patients, but also in cycling patients receiving high doses of GnRH antagonist. The Ganirelix dose finding study demonstrated very low implantation rates in the high dose groups (1 mg, 2 mg).

The stimulation dynamics in these patients were remarkable for very low E2 and LH levels on the day of hCG. In fact, a functional state of hypogonadotropic hypogonadism is achieved, explaining the poor clinical results (1.5% implantation rate under 2 mg Ganirelix). The same protocol was repeated with added Luveris resulting in excellent pregnancy rates.

The recommended daily dose of GnRH antagonist is 0.25 mg which on the average provides a protection from premature LH surge, with moderate suppression of LH. Therefore, most patients do not need supplemented LH after the antagonist is initiated.

However, there is a subgroup of patients who hyper-respond to the antagonist (in 0.25 mg dose) with a sharp decrease in LH. This explains contradictory findings in the available studies. The basic assumption in the background of this proposal is that there is a wide range of pituitary responses to GnRH antagonist. Obeying a bell-shape curve, most women have an average response, however, some hypo-respond might ovulate prematurely, and others hyper-respond. In the latter cases, pituitary response will behave as if exposed to a higher dose.

How to identify an exposure to a presumed higher dose?

Below is a figure from the original paper. A close look indicates that the immediate response to all Ganirelix doses are similar in terms of LH drop, however, the big difference lies in the pituitary recovery 24 hours post Ganirelix dose.

While small doses allow for a quick recovery to almost pre-treatment LH levels, high doses result in incomplete recovery. Hence, it is reasonable to speculate that the high response to 0.25 mg dose will lead to slow or incomplete recovery of LH levels 24 hours post the initial dose.

It is estimated that about 15% of patients are antagonist hyper-responders. Efforts to individualize patient protocol must target this group as candidates for supplemented LH. This estimate is similar to study findings: Huirne et al Human Reproduction 2005, 20: 359.


Condition Intervention Phase
Infertility, Female Infertility, Male Infertility
Drug: Recombinant LH (Luveris)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist

Resource links provided by NLM:


Further study details as provided by Assuta Hospital Systems:

Primary Outcome Measures:
  • The primary endpoint will be the proportion of patients who, after receiving Cetrotide after 4 or 5 days of Gonal -F stimulation, are severely down-regulated. [ Time Frame: 24 hours after first administration of Cetrotide. ] [ Designated as safety issue: No ]
    If LH drops more than 50% from its baseline (as measured before Cetrotide) the patient is defined as "Cetrotide hyper-responder"


Enrollment: 50
Study Start Date: June 2010
Study Completion Date: August 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GnRH antagomnist hyper-responders
Those defined as hyper-responders will be given recombinant LH.
Drug: Recombinant LH (Luveris)
150 IU recombinant LH daily.
Other Name: Luveris

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. The patient is eligible for IVF and will be treated according to the Summary of Product Characteristics (SmPC) and routine practice in participating centres.

    2. The patient must be willing and able to comply with the protocol for the duration of the study.

    3. The patient has given written informed consent with the understanding that the consent may be withdrawn by her at any time without prejudice for her future medical care.

    4. Must be hyper-responder to antagonist according definition

Exclusion Criteria:

  1. Ovarian, uterine or mammary cancer.
  2. Tumours of the hypothalamus and pituitary gland.
  3. Uterine myoma requiring treatment.
  4. Ovarian enlargement or cyst of unknown aetiology.
  5. A clinically significant systemic disease.
  6. Abnormal gynaecological bleeding of undetermined origin.
  7. Known allergy or hypersensitivity to human gonadotrophin preparations.
  8. Entered previously into this study or simultaneous participation in another clinical study.
  9. Age > 39 yrs,
  10. BMI > 32 kg/m2,
  11. Patient with no cycles: PCOS or an anovulatory patient. -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01936077

Locations
Israel
Women Health Center, Maccabi Health Services
Haifa, Israel
Sponsors and Collaborators
Assuta Hospital Systems
Maccabi Healthcare Services, Israel
  More Information

No publications provided

Responsible Party: shahar kol, Director, fertility clinic, Women Health Center, Haifa, Israel, Assuta Hospital Systems
ClinicalTrials.gov Identifier: NCT01936077     History of Changes
Other Study ID Numbers: 2010036
Study First Received: October 28, 2010
Last Updated: September 2, 2013
Health Authority: Israel: Ethics Commission

Keywords provided by Assuta Hospital Systems:
Infertility, IVF, ovarian stimulation, rec LH, GnRH antagonist

Additional relevant MeSH terms:
Infertility
Infertility, Female
Infertility, Male
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on August 20, 2014